MedPath

Stem Cells and Resynchronization Cardiac

Phase 1
Conditions
Heart Failure
Registration Number
NCT00800657
Lead Sponsor
Instituto de Molestias Cardiovasculares
Brief Summary

Same patients with dilated myocardiopathies with large areas of fibrosis has not been as successful after Cardiac Resynchronization Therapy, for Heart Failure patients in functional class III or IV. Therefore the investigators have decided to associate the Stem-Cell implant with Cardiac Resynchronization Therapy in these patients.

Detailed Description

About 120cc of blood are collected from the iliac bone marrow under epidural anesthesia.In the cell therapy lab this blood is harvested and mononuclear cells are separated.This procedure takes roughly 4 hours.After dilution the mononuclear cells are injected into the cardiac muscles with fibroses area through 20 shots.This procedure is indicated for patients with cardiac ischemia and left ventricular dysfunction(desynchrony), on whom all the others known therapies have failed.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Ejection Fraction(EF)-(Eco- Sympson):It is the comparison of these measurements between late pre and post operative. NYHA: Comparison of these measurements between late pre and post operative.24 months
Secondary Outcome Measures
NameTimeMethod
Ejection Fraction (Echo/Sympson) and functional class(NYHA).24 months.

Trial Locations

Locations (1)

Imc - Instituto de Moléstias Cardiovasculares

🇧🇷

São José do Rio Preto, São Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath